Skip to main content
Clinical Trials/ACTRN12623000618651
ACTRN12623000618651
Recruiting
Phase 1

Exploratory trial to assess the efficacy and safety of Psilocybin-Assisted Psychotherapy (PAP) involving family-members compared to standard PAP, in adults with treatment-resistant major depressive disorder. (TRMDD).

Reset Mind Science0 sites60 target enrollmentJune 6, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Treatment-resistant major depressive disorder (TRMDD).
Sponsor
Reset Mind Science
Enrollment
60
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 6, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Reset Mind Science

Eligibility Criteria

Inclusion Criteria

  • Participant must be over 18 years of age inclusive, up to 65 years old at
  • the time of signing the informed consent.
  • Participant is able to read, understand and agree with the procedures of
  • Participants must be diagnosed with major depressive disorder and have
  • moderate to severe depression (17\+ on the 17\-item Hamilton Depression
  • Rating scale \[HAM\-D17]).
  • Participants have failed to respond to two adequate courses of
  • antidepressant treatment of different pharmacological classes lasting at least
  • 6 weeks within the current depressive episode and have not been subject to
  • Electroconvulsive therapy (ECT) within 6 months prior to the study.

Exclusion Criteria

  • Participants unable to provide written informed consent.
  • Participants with history of current or previously diagnosed psychotic
  • disorder, or bipolar disorder.
  • Immediate family member with a diagnosed psychotic disorder.
  • Participants that are pregnant or breastfeeding. Positive pregnancy test
  • at screening or prior to any psilocybin administration or refusal to have an
  • on\-site B\-HCG pregnancy test prior to any psilocybin administration.
  • Participants who may have sexual contact, without contraceptive
  • measures, with a person who may become pregnant during or within 90 days
  • (or 3 months) of cessation of the psilocybin IMP.

Outcomes

Primary Outcomes

Not specified

Similar Trials